The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).
David F. McDermott
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Charles G. Drake
Consultant or Advisory Role - Amplimmune; Bristol-Myers Squibb; Dendreon
Stock Ownership - Amplimmune
Other Remuneration - Bristol-Myers Squibb
Mario Sznol
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Toni K. Choueiri
No relevant relationships to disclose
John Powderly
Consultant or Advisory Role - Bristol-Myers Squibb; Medarex
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
David C. Smith
Research Funding - Bristol-Myers Squibb
Jon Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Dan McDonald
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Georgia Kollia
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb (B)
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Michael B. Atkins
Consultant or Advisory Role - Bristol-Myers Squibb; CureTech; Merck